Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window

Zhang, Huiying; Zheng, Lei

doi:10.6061/clinics/2021/e2728

Cited by 9 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 80 patients with ischemic stroke who were hospitalized in Zhoushan Hospital from October 2019 to May 2022 were included in the study, including 40 patients with PCI and 40 patients with NPCI. The inclusion criteria were as follows: (1) patients admitted to the Acute Stroke Unit within 24 h of CI onset; (2) age ≥18 years with no previous stroke history; (3) PCI was defined as the neurological deficits that did not show any improvement and continued to progress within 1 week under regular treatment, with the NIHSS score increased by at least 2 points 13,14 . The exclusion criteria were as follows: (1) patients with severe impairment of consciousness, transient ischemic attack, hemorrhagic stroke, subarachnoid hemorrhage, intracranial infection, intracranial hemorrhage, intracranial tumor, trauma, or neurodegenerative disease; (2) severe cardiac, hepatic, and renal insufficiency; (3) comorbid hematologic disease, malignancy, autoimmune disease; (4) more than two consecutive BP recordings missing (i.e., with any interval more than 4 h between recordings).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Hemodynamic changes in progressive cerebral infarction: An observational study based on blood pressure monitoring

Li,

Wu,

Dong

et al. 2024

J of Clinical Hypertension

View full text Add to dashboard Cite

Progressive cerebral infarction (PCI) is a common complication in patients with ischemic stroke that leads to poor prognosis. Blood pressure (BP) can indicate post‐stroke hemodynamic changes which play a key role in the development of PCI. The authors aim to investigate the association between BP‐derived hemodynamic parameters and PCI. Clinical data and BP recordings were collected from 80 patients with cerebral infarction, including 40 patients with PCI and 40 patients with non‐progressive cerebral infarction (NPCI). Hemodynamic parameters were calculated from the BP recordings of the first 7 days after admission, including systolic and diastolic BP, mean arterial pressure, and pulse pressure (PP), with the mean values of each group calculated and compared between daytime and nighttime, and between different days. Hemodynamic parameters and circadian BP rhythm patterns were compared between PCI and NPCI groups using t‐test or non‐parametric equivalent for continuous variables, Chi‐squared test or Fisher's exact test for categorical variables, Cox proportional hazards regression analysis and binary logistic regression analysis for potential risk factors. In PCI and NPCI groups, significant decrease of daytime systolic BP appeared on the second and sixth days, respectively. Systolic BP and fibrinogen at admission, daytime systolic BP of the first day, nighttime systolic BP of the third day, PP, and the ratio of abnormal BP circadian rhythms were all higher in the PCI group. PCI and NPCI groups were significantly different in BP circadian rhythm pattern. PCI is associated with higher systolic BP, PP and more abnormal circadian rhythms of BP.

show abstract

Section: Methodsmentioning

confidence: 99%

“…(3) PCI was defined as the neurological deficits that did not show any improvement and continued to progress within 1 week under regular treatment, with the NIHSS score increased by at least 2 points. 13,14 The exclusion criteria were as follows: (…”

mentioning

confidence: 99%

Hemodynamic changes in progressive cerebral infarction: An observational study based on blood pressure monitoring

Li,

Wu,

Dong

et al. 2024

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…The observation period involves vigilant monitoring for any stroke-related events occurring within 30 days post-procedure. This includes ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, and progressive stroke (de ned as an increase of ≥ 2 points in the NIHSS score during the follow-up period) 12,13 . Additionally, mortality outcomes were documented and tracked.…”

Section: Methodsmentioning

confidence: 99%

Safety Assessment of Symptomatic Intracranial Atherosclerotic Stenosis: A Comparison between Sole Balloon Angioplasty and Medical Treatment

Cao,

Wen,

Cao

et al. 2024

Preprint

View full text Add to dashboard Cite

Patients with symptomatic intracranial arterial stenosis (sICAS) will likely face perioperative risks with stent placement and recurrence with medication. Simple balloon angioplasty (SBA), as a less invasive and safer alternative to stent placement, may offer an effective treatment option for sICAS. This study aimed to assess the perioperative safety of SBA compared to medication for sICAS. A retrospective analysis was conducted on sICAS patients admitted to the Department of Neurology, Jiangxi Provincial People's Hospital, between January 2020 and December 2021, within 60 days of onset. Patients with severe stenosis (70% to 99% rate), confirmed by cerebral angiography, were divided into medication and SBA groups. Demographic data, medical history, NIH Stroke Scale (NIHSS) scores at onset, responsible vessels, degree of vascular stenosis, postoperative residual stenosis rate, and any stroke or death within 30 days postoperatively were assessed. The study included 91 patients, with 51 in the medication group (38 males, mean age 58.06±1.58 years) and 40 in the SBA group (24 males, mean age 60.95±1.37 years). There were no significant differences in demographics, medical history, NIHSS scores, or degree of vascular stenosis (all P > 0.05). All SBA patients underwent successful balloon angioplasty, with 8 cases (20%) requiring a stent placement due to significant post-dilation stenosis regression or dissection affecting blood flow. Within 30 days postoperatively, 2 patients (3.9%) in the medication group experienced progressive stroke, while 3 patients (7.5%) in the SBA group experienced endpoint events, including 2 cases of new-onset infarction and 1 case of subarachnoid hemorrhage. There was no statistically significant difference in endpoint event occurrence between the groups (P > 0.05), and no deaths occurred. In conclusion, SAB in sICAS patients did not significantly increase the risk of stroke within 30 days postoperatively compared to medication treatment. Long-term efficacy warrants further investigation.

show abstract

“…It has been used in the treatment of cerebral ischemic stroke with promising therapeutic outcomes ( Zhang et al, 2013 ; Bhatia et al, 2021 ). Presently, ozagrel combined therapy is widely used in clinical practice, especially in combination with traditional Chinese medicine formulas or monomers ( Park et al, 2015 ; Wada et al, 2016 ; Zhang and Zheng, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Design, synthesis, and evaluation of the novel ozagrel–paeonol codrug with antiplatelet aggregation activities as a potent anti-stroke therapeutic agent

Zuo,

Yan,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Introduction: Ischemic stroke is the second most common chronic disease worldwide and is associated with high morbidity and mortality. Thromboembolism and platelet aggregation are the most characteristic features of stroke. Other than aspirin, no standard, accepted, or effective treatment for acute ischemic stroke has been established. Consequently, it is essential to identify novel therapeutic compounds for this condition.Methods: In this study, novel ozagrel/paeonol-containing codrugs were synthesized and characterized using 1H-NMR, 13C-NMR, and mass spectroscopy. Their antiplatelet aggregation activity was evaluated, with compound PNC3 found to exhibit the best effect. Subsequently, studies were conducted to assess its neuroprotective effect, pharmacokinetic properties and model its binding mode to P2Y12 and TXA2, two proteins critical for platelet aggregation.Results: The results indicated that PNC3 has good bioavailability and exerts protective effects against oxygen-glucose deprivation injury in PC12 cells. Molecular docking analysis further demonstrated that the compound interacts with residues located in the active binding sites of the target proteins.Conclusion: The codrugs synthesized in this study display promising pharmacological activities and have the potential for development as an oral formulation.

show abstract

Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window

Abstract: Zhang H, Zheng L. Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window. Clinics (Sao Paulo).

Cited by 9 publications

References 30 publications

Hemodynamic changes in progressive cerebral infarction: An observational study based on blood pressure monitoring

Hemodynamic changes in progressive cerebral infarction: An observational study based on blood pressure monitoring

Safety Assessment of Symptomatic Intracranial Atherosclerotic Stenosis: A Comparison between Sole Balloon Angioplasty and Medical Treatment

Design, synthesis, and evaluation of the novel ozagrel–paeonol codrug with antiplatelet aggregation activities as a potent anti-stroke therapeutic agent

Contact Info

Product

Resources

About